ValuentumAd

Official PayPal Seal

Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Sep 3, 2019
Triple-A Rated J&J’s Opioid Liabilities Likely More Than Priced In
Image Source: J&J. Shares of J&J have settled into the high-$120s at the time of this writing, well below our ~$150 fair value estimate. We’re going to stick with J&J in both the Dividend Growth Newsletter portfolio and Best Ideas Newsletter portfolio at this time.
Aug 27, 2019
Elanco Buys Bayer’s Animal Health Unit, Gaining Scale and Greater Exposure to the “Humanization of Pets” Trend
On August 20, Elanco Animal Health Inc agreed to acquire Bayer AG’s animal health unit for $7.6 billion (at the time the deal was announced) through a cash and stock deal. This is a transformative deal for Elanco and one that will create a real competitor to Zoetis' and Merck’s animal health units. For Bayer, the company can now pivot to segments where it has stronger competitive advantages while also raising cash to cover potential Roundup-related legal liabilities (which could be enormous). We will be monitoring the space going forward but are staying firmly on the sidelines for now.
Aug 26, 2019
The Valuentum Team Talks Powell Speech and Threat of Global Recession
Last week, China issued retaliatory tariffs on US goods, and Trump responded in kind, escalating trade tensions. Caught in the middle of this US-China trade war is the Fed, however. Let’s sit down with the Valuentum team and kick things off with our thoughts on Fed Chairman Powell’s speech, Challenges for Monetary Policy issued August 23 in Jackson Hole, WY.
Aug 22, 2019
What’s on the Valuentum Team’s Mind?
Let’s get the Valuentum team’s thoughts on recent developments.
Aug 16, 2019
Ebix Might Be a Value Trap
Image Source: Ebix Inc -- IR Presentation. We think Ebix, even after its fall, has the makings of a value trap, and we caution our readers that there may be better opportunities out there. Why catch a falling knife with a low dividend yield?
Aug 13, 2019
Thought Piece: The Hidden Advantage
Image Source: Kamilla Oliveira. As activist investing proliferates, investors are becoming more and more familiar with celebrity investing gurus such as Carl Icahn and David Einhorn. Let’s examine how these investing giants have carved out a unique structural advantage over mom-and-pop investors. This article was originally published in June 2014.
Aug 9, 2019
Dividend Increases/Decreases for the Week Ending August 9
Let's take a look at companies that raised/lowered their dividend this week.
Aug 7, 2019
Join the Conversation on the Market Plunge
The Valuentum team shares its thoughts on the recent surge in volatility and collapse in interest rates amid a trade and currency war between two of the largest economies in the world, the US and China.
Aug 1, 2019
How About the New Vette? General Motors Bouncing Back
Image Source: GM Chevrolet Next-Generation Corvette, 2020 Stingray revealed July 18. Shares of General Motors held up well in an otherwise weak market August 1 after posting a solid second quarter 2019 earnings report. The new Vette looks sharp.
Jul 19, 2019
Microsoft Posts a Great Quarter to Round Out a Great Fiscal Year
Image Source: Microsoft Corp. We remain very optimistic on Microsoft’s future dividend growth trajectory, and we would like to note the upper end of our fair value estimate range stands at $154 per share of Microsoft. The market at-large seems largely supportive of Microsoft’s latest earnings, and so are we.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.